July 29th, 2013
Selections from Richard Lehman’s Literature Review: July 29th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include riociguat for chronic thromboembolic pulmonary hypertension, renal outcomes associated with invasive vs. conservative management of ACS, statins and musculoskeletal conditions, arthropathies, and injuries, and more.
July 25th, 2013
Novel Pulmonary Hypertension Drug Shows Modest Promise in Phase 3 Trials
Larry Husten, PHD
A new drug appears to have promising — but not game-changing — effects in people with two forms of pulmonary hypertension. Riociguat, a soluble guanylate cyclase stimulator under development by Bayer, is thought to have vasodilating, antiproliferative, and antifibrotic effects. Results of two phase 3, placebo-controlled trials were published today in the New England Journal of Medicine. CHEST-1 studied the clinical […]
July 25th, 2013
The Changing Landscape of Pulmonary Hypertension
John Ryan, MD
Two multicenter clinical trials published in the New England Journal of Medicine explore the role of a new oral pulmonary vasodilator in pulmonary hypertension.
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults